OPKO Health (NASDAQ:OPK) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 73,903,777 shares, an increase of 6.7% from the May 31st total of 69,237,227 shares. Currently, 22.7% of the shares of the company are short sold. Based on an average daily trading volume, of 4,775,406 shares, the short-interest ratio is currently 15.5 days.
In other news, Director Robert Scott Fishel purchased 10,000 shares of the company’s stock in a transaction on Friday, April 13th. The stock was acquired at an average cost of $3.02 per share, for a total transaction of $30,200.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Phillip Md Et Al Frost purchased 153,000 shares of the company’s stock in a transaction on Tuesday, April 3rd. The stock was purchased at an average price of $3.00 per share, with a total value of $459,000.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $9,206,853. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 1,042,701 shares of company stock valued at $3,504,365. 42.74% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Castleview Partners LLC purchased a new stake in OPKO Health during the first quarter valued at $103,000. Ellington Management Group LLC purchased a new stake in OPKO Health during the fourth quarter valued at $112,000. First Trust Advisors LP purchased a new stake in OPKO Health during the fourth quarter valued at $154,000. Xact Kapitalforvaltning AB purchased a new stake in OPKO Health during the fourth quarter valued at $179,000. Finally, BDO Wealth Advisors LLC raised its stake in OPKO Health by 12,000.0% during the first quarter. BDO Wealth Advisors LLC now owns 60,500 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 60,000 shares in the last quarter. Hedge funds and other institutional investors own 23.81% of the company’s stock.
Shares of OPKO Health opened at $4.81 on Wednesday, Marketbeat reports. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.10 and a quick ratio of 0.94. OPKO Health has a fifty-two week low of $2.66 and a fifty-two week high of $7.24. The firm has a market cap of $2.56 billion, a P/E ratio of -16.59 and a beta of 1.67.
OPKO Health (NASDAQ:OPK) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.05. OPKO Health had a negative net margin of 31.27% and a negative return on equity of 8.76%. The firm had revenue of $254.90 million during the quarter, compared to analyst estimates of $236.90 million. During the same quarter in the prior year, the business earned ($0.06) earnings per share. OPKO Health’s revenue for the quarter was down 4.3% on a year-over-year basis. research analysts anticipate that OPKO Health will post -0.27 earnings per share for the current year.
A number of equities analysts have weighed in on the stock. BidaskClub upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 12th. Zacks Investment Research lowered shares of OPKO Health from a “buy” rating to a “hold” rating in a research report on Friday, May 25th. ValuEngine upgraded shares of OPKO Health from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Barrington Research restated a “buy” rating and set a $7.00 target price on shares of OPKO Health in a research report on Wednesday, May 9th. Finally, JPMorgan Chase & Co. lowered shares of OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 target price for the company. in a research report on Friday, March 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $10.21.
About OPKO Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.